Impact of prolonged use of angiotensin receptor-neprilysin inhibitors versus angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in patients with heart failure reduced ejection frac

21 May 2023 (13:00 - 13:45)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Bo Eun PARK

Kyungpook National University Hospital, Daegu (Korea (Republic of))

7 More presentations in this session

Presentation thumbnail

The usefulness of end-expiratory oxygen partial pressure as a prognostic indicator in patients with heart failure with reduced ejection fraction

Doctor T. Nakade (Tokyo, JP)

Abstract Slides

Presentation thumbnail

SGLT2 inhibitors in heart failure with reduced ejection fraction without diabetes mellitus: why are patients outside the magic circle?

Doctor D. Santoro (Pavia, IT)

Abstract Slides

Presentation thumbnail

Integrated transcriptomic and regulatory RNA sequencing and machine-learning driven analyses identify molecular signatures underlying human heart failure

Doctor J. Gulia (Bengaluru, IN)

Abstract Slides

Presentation thumbnail

Cardiac amyloidosis patients with reduced ejection fraction have an increase morbimortality

Doctor F. Bauer (Le Kremlin-Bicetre, FR)

Abstract Slides

Presentation thumbnail

Ivabradine improves survival in children with severe chronic heart failure

Doctor R. Adorisio (Rome, IT)

Abstract Slides

Access the full session

Session thumbnail

Heart failure with reduced ejection fraction (HFrEF) 2

The Event

Event poster

Heart Failure 2023

21 May 2023 13:00 CET

You may be interested in

Webinar

Advanced heart failure therapy in HF patients with preserved and mildly reduced ejection fraction

Congress Session

Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

Congress Session

Transforming heart failure care: unlocking new pathways

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources